XML 22 R11.htm IDEA: XBRL DOCUMENT

Inventories, net

9 Months Ended

Feb. 23, 2025

Inventories primarily consist of in-process and finished goods related to sterile injectable pharmaceutical products in syringes, vials and cartridges. This includes premium, pharmaceutical grade HA in bulk form as well as formulated and filled syringes, vials and cartridges for injectable products used in treating a broad spectrum of medical conditions and procedures.

Inventories are stated at the lower of cost (using the first-in, first-out method) or net realizable value. Inventory costs include the purchase price of raw materials, and additionally for work in process and finished goods, direct labor costs and allocated portions of indirect labor, property, plant and equipment costs needed in the manufacturing process.

Inventories consisted of the following:


	February 23, 2025		May 26, 2024
Finished goods	$	13,483	$	14,924
Raw materials	12,075		13,140
Work in process	9,038		11,915


Inventories, net	$	34,596	$	39,979

Adjustments to inventory are determined at the raw materials, work-in-process, and finished good levels to reflect obsolescence or impaired balances. Factors influencing inventory obsolescence include changes in demand, product life cycle, product pricing, physical deterioration, and quality concerns.